{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-169190","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.071267+00:00","generated_at":"2026-06-13T20:39:25.710770+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Madrigal appoints Julian Baker as Chairman, adds two Baker Bros. affiliates to board","bullets":["Keith Gollust and David Milligan resigned as Class III directors effective June 15, 2023; no disagreement cited.","Julian Baker appointed independent Chairman; Raymond Cheong also appointed as Class III director.","Both new directors are affiliated with Baker Bros. Advisors LP, a significant shareholder.","Baker Bros. waived director nomination rights under Securities Purchase Agreement while Baker or Cheong serve.","CEO Paul Friedman remains; Chairman and CEO roles separated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-169190","json":"https://secwatch.observer/filing/0001193125-23-169190.json","markdown":"https://secwatch.observer/filing/0001193125-23-169190.md","text":"https://secwatch.observer/filing/0001193125-23-169190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523169190/0001193125-23-169190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523169190/d480541d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:39:25.710770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a33a7ff27","claim":"David Milligan resigned as Class III Director at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"On June 15, 2023, Keith R. Gollust and David Milligan, Ph.D., each Class III directors on the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523169190/0001193125-23-169190-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"405c45abfe","claim":"Raymond Cheong was appointed as Class III Director at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"On June 15, 2023, Julian Baker and Raymond Cheong were appointed to the Board as Class III directors, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523169190/0001193125-23-169190-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"711076dba0","claim":"Keith R. Gollust resigned as Class III Director at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"On June 15, 2023, Keith R. Gollust and David Milligan, Ph.D., each Class III directors on the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523169190/0001193125-23-169190-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"94fb6d53e1","claim":"Julian Baker was appointed as Director and Chairman at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"Julian Baker was appointed to serve as the independent Chairman of the Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523169190/0001193125-23-169190-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director and Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}